Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 7:2018:7510174.
doi: 10.1155/2018/7510174. eCollection 2018.

MicroRNA in Sjögren's Syndrome: Their Potential Roles in Pathogenesis and Diagnosis

Affiliations
Review

MicroRNA in Sjögren's Syndrome: Their Potential Roles in Pathogenesis and Diagnosis

M Reale et al. J Immunol Res. .

Abstract

Sjögren's syndrome (SS) or sicca syndrome was described by Swedish ophthalmologist Sjögren in the year 1933 for the first time. The etiology of the SS is multifunctional and includes a combination of genetic predisposition and environmental as well as epigenetic factors. It is an autoimmune disease characterized by features of systemic autoimmunity, dysfunction, and inflammation in the exocrine glands (mainly salivary and lacrimal glands) and lymphocytic infiltration of exocrine glands. In fact, the involvement of lacrimal and salivary glands results in the typical features of dry eye and salivary dysfunction (xerostomia). Only in one-third of the patients also present systemic extraglandular manifestations. T cells were originally considered to play the initiating role in the autoimmune process, while B cells were restricted to autoantibody production. In recent years, it is understood that the roles of B cells are multiple. Moreover, autoantibodies and blood B cell analysis are major contributors to a clinical diagnosis of Sjögren's syndrome. Recently, there has been rising interest in microRNA implication in autoimmunity. Unfortunately, to date, there are only a few studies that have investigated their participation in SS etiopathogenesis. The purpose of this work is to gather the data present in the literature to clarify this complex topic.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Hu S., Vissink A., Arellano M., et al. Identification of autoantibody biomarkers for primary Sjögren’s syndrome using protein microarrays. Proteomics. 2011;11(8):1499–1507. doi: 10.1002/pmic.201000206. - DOI - PMC - PubMed
    1. Nair J. J., Singh T. P. Sjögren’s syndrome: review of the aetiology, pathophysiology & potential therapeutic interventions. Journal of Clinical and Experimental Dentistry. 2017;9(4):e584–e589. doi: 10.4317/jced.53605. - DOI - PMC - PubMed
    1. Carsons S. E., Bhimji S. S. Sjogren Syndrome. Treasure Island, FL, USA: StatPearls Publishing LLC; 2017. Bookshelf ID: NBK431049. - PubMed
    1. Fox R. I. Sjögren’s syndrome. Lancet. 2005;366(9482):321–331. doi: 10.1016/S0140-6736(05)66990-5. - DOI - PubMed
    1. García-Carrasco M., Fuentes-Alexandro S., Escárcega R. O., Salgado G., Riebeling C., Cervera R. Pathophysiology of Sjögren’s syndrome. Archives of Medical Research. 2006;37(8):921–932. doi: 10.1016/j.arcmed.2006.08.002. - DOI - PubMed

LinkOut - more resources